Zydus Nash

Prospective, Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium

Study phase: Other

Study phase (if other): 2b

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

Males and Females between 18 and 75 years of age

Primary disease category: Liver

Secondary disease categories: Liver

Sponsor: Zydus Therapeutics, Inc

Protocol number: Saro.20.002

Projected enrollment dates: October 2021 to October 2023

Official study title: Zydus Nash 2B